Compare TPB & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPB | COAG |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2015 | 2026 |
| Metric | TPB | COAG |
|---|---|---|
| Price | $73.43 | $42.84 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $115.00 | N/A |
| AVG Volume (30 Days) | 207.8K | ★ 286.6K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ 45.33 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $463,062,000.00 | N/A |
| Revenue This Year | $13.68 | N/A |
| Revenue Next Year | $11.32 | N/A |
| P/E Ratio | $23.54 | ★ N/A |
| Revenue Growth | ★ 28.39 | N/A |
| 52 Week Low | $65.80 | $27.47 |
| 52 Week High | $146.90 | $55.42 |
| Indicator | TPB | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 31.84 | 38.82 |
| Support Level | $71.22 | $28.51 |
| Resistance Level | $91.65 | $53.01 |
| Average True Range (ATR) | 3.10 | 3.43 |
| MACD | -1.32 | -0.83 |
| Stochastic Oscillator | 4.62 | 0.28 |
Turning Point Brands Inc operates as a manufacturer, marketer, and provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum, including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments, namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.